Caribou Biosciences, Inc.

Uses CRISPR genome editing to create off-the-shelf CAR-T cell therapies for cancer.

CRBU | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 2929 7TH STREET, SUITE 105, 94710 BERKELEY
Website:: https://www.cariboubio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company developing transformative, genome-edited cell therapies. A leader in the CRISPR field, the company utilizes its proprietary chRDNA (CRISPR hybrid RNA-DNA) technology to engineer complex, multiplex edits with high precision and specificity. Its primary focus is on creating allogeneic, or "off-the-shelf," CAR-T cell therapies for patients with hematologic malignancies and other devastating diseases. A key component of its strategy is "armoring" these therapies through genome editing techniques, such as immune cloaking and checkpoint disruption, to enhance their persistence and anti-tumor activity. The company was co-founded by CRISPR pioneer and 2020 Nobel laureate Jennifer Doudna.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Caribou Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Caribou Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Caribou Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Arcellx, Inc. Engineering controllable cell therapies for cancer and autoimmune diseases.	United States of America	ACLX
Arctic Bioscience Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.	Norway	ABS
ArcticZymes Technologies Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.	Norway	AZT
Arcturus Therapeutics Holdings Inc. Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.	United States of America	ARCT
Arcus Biosciences, Inc. A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.	United States of America	RCUS
Arcutis Biotherapeutics, Inc. Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.	United States of America	ARQT
ARDELYX, INC. Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.	United States of America	ARDX
ARECOR THERAPEUTICS PLC Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.	United Kingdom	AREC
argenx SE Develops first-in-class antibody therapies for severe autoimmune diseases.	Netherlands	1AE
ARGENX SE Develops antibody-based therapies for severe autoimmune diseases, including its lead drug VYVGART.	United States of America	ARGX